Ceyda Çaytemel

Ceyda Çaytemel

Auto-generated profile, based on publicly available information

Ceyda Çaytemel

School of Medicine, Department of Dermatology and Venereology Istanbul Acibadem University Istanbul Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2021 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
CÇCeyda Çaytemel
Ceyda Çaytemel
OEOzan Erdem
Ozan Erdem
ŞAŞenay Ağırgöl
Şenay Ağırgöl
ZTZafer Türkoğlu
Zafer Türkoğlu

27 December 2020 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
CÇCeyda Çaytemel
Ceyda Çaytemel
BBBaşak Baykut
Başak Baykut
ŞAŞenay Ağırgöl
Şenay Ağırgöl
NCNazlı Caf
Nazlı Caf
FDFiliz Topaloğlu Demir
Filiz Topaloğlu Demir
EUEsen Gül Uzuner
Esen Gül Uzuner

25 October 2022 in International Journal of Dermatology
Verified
Journal Article
Closed access
ÖKÖmer Kutlu
Ömer Kutlu
YDYuhanize Taş Demircan
Yuhanize Taş Demircan
KYKenan Yıldız
Kenan Yıldız
GKGӧknur Kalkan
Gӧknur Kalkan
DDDuriye Deniz Demirseren
Duriye Deniz Demirseren
AKAyşe Serap Karadağ
Ayşe Serap Karadağ

8 February 2021 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
PDF file
SASenay Agirgol
Senay Agirgol
CÇCeyda Çaytemel
Ceyda Çaytemel
AKAhmet Şah Kolan
Ahmet Şah Kolan
HVHüseyin Vural
Hüseyin Vural
CONTEXT: Various skin manifestations have been reported in coronavirus disease. It may be difficult to determine the etiology of these lesions in view of the increased frequency of handwashing during the pandemic, along with occurrences of irritant contact dermatitis and allergic contact dermatitis due to disinfectant use; usage of herbal medicine and supplements to strengthen the immune system; and urticarial or maculopapular drug eruptions due to COVID-19 treatment. The variety of associated skin manifestations seen with COVID-19 makes it challenging to identify virus-specific skin manifestations. Petechiae, purpura, acrocyanosis and necrotic and non-necrotic purpura, which can be considered as manifestations of vascular involvement on the skin, have been reported. CASE REPORT: Here, we report a case of eruptive cherry angiomas, which was thought to have developed due to COVID-19, with a papulovesicular rash on distal extremities that progressed over time to reticular purpura. CONCLUSION: The case presented had a papulovesicular rash at the onset, which evolved to retiform purpura, and eruptive cherry angiomas were observed. It should be kept in mind that dermatological signs may vary in patients with COVID-19.

1 January 2020 in Northern Clinics of Istanbul
Verified
Journal Article
Open access
CÇCeyda Çaytemel
Ceyda Çaytemel
Sebaceous hyperplasia (SH) is a benign tumor with telangiectasia on it, yellowish or skin-colored, with papulosis. Besides genetic factors, aging, ultraviolet rays, sex hormones, calcineurin inhibitors, such as cyclosporin, tacrolimus and systemic steroids, play a role in the development of sebaceous hyperplasia. Cyclosporin is widely used in organ transplant patients. Acne, keratosis pilaris, sebaceous hyperplasia and epidermoid cysts, which are rare side effects, are frequently seen in renal transplant patients and it is suggested that the pilosebaceous unit develops as a result of occlusion with keratinous material. It is thought that cyclosporine causes these side effects by increasing the secretion of sebum and 5-alpha reductase enzyme activity. In this case study, wepresent here a 36-year-old female patient who had been on cyclosporine treatment for 25 years and had a large number of yellowish, umblike papules on her face for 20 years. She had been diagnosed with cyclosporin triggered by clinical and histopathological findings. The patient was started on 40 mg/day (0.6 mg/kg/day) systemic isotretinoin treatment, and after two months treatment, the patient had almost complete regression of the lesions. Systemic isotretinoin is effective and easy to treat treatment for patients with multiple lesions, especially when compared to other treatments. In addition, all of the cases reported in the literature are male, and this report presents the first female transplant patient with SH, which is induced by cyclosporine use.

27 June 2022 in Medical Bulletin of Haseki
Verified
Journal Article
Closed access
SASenay Agirgol
Senay Agirgol
TATugba Ozkok Akbulut
Tugba Ozkok Akbulut
FDFiliz Topaloglu Demir
Filiz Topaloglu Demir
ECEvrim Cakir
Evrim Cakir
AGAlper Gumus
Alper Gumus
CCCeyda Caytemel
Ceyda Caytemel